The ins and outs of mitochondrial dysfunction in NASH

Diabetes and Metabolism

Volumn 30, Issue 2, 2004, Pages 121-138

  Fromenty, B ^a   Robin, M A ^a   Igoudjil, A ^a   Mansouri, A ^a   Pessayre, D ^a  

^a INSERM   (France)

Author keywords

Cytokines; Lipid peroxidation; Mitochondria; Reactive oxygen species; Steatohepatitis; Steatosis

Indexed keywords

AMIODARONE; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTIRETROVIRUS AGENT; CYTOKINE; DIDANOSINE; DIETHYLAMINOETHOXYHEXESTROL; FAS LIGAND; INSULIN; MITOCHONDRIAL DNA; PERHEXILINE; REACTIVE OXYGEN METABOLITE; STAVUDINE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZIDOVUDINE;

APOPTOSIS; CELL DEATH; DIETARY INTAKE; DRUG INDUCED DISEASE; EXERCISE; FATTY ACID OXIDATION; GENETIC POLYMORPHISM; HUMAN; INCIDENCE; INSULIN RESISTANCE; LIPID PEROXIDATION; LIVER CELL; MITOCHONDRIAL DNA DISORDER; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; STEATOSIS;

EID: 2642583241     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70098-8     Document Type: Review

References (180)

1. Kopelman PG. Obesity as a medical problem. Nature, 2000, 404, 635-43.
2. Diehl AM. Nonalcoholic steatohepatitis. Sem Liver Dis, 1999, 19, 221-9.
3. Pessayre D, Berson A, Fromenty B, Mansouri A. Mitochondria in steatohepatitis. Sem Liver Dis, 2001, 21, 57-69.
4. Pessayre D. Mitochondrial injury in steatohepatitis. In: Frederick J Suchy, J Gregory Fitz, Jacquelyn J Maher, eds. Course Directors, American Association for the Study of Liver Diseases Postgraduate Course 2002: Mechanisms of Acute and Chronic Liver Diseases: Implications for Diagnosis, Pathogenesis and Treatment. AASLD Post-graduate Course, 2002, 97-103.
5. Pessayre D, Mansouri A, Fromenty B. Mitochondrial dysfunction in steatohepatitis. Am J Physiol Gastrointest Liver Physiol, 2002, 282, G193-9.
6. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology, 2003, 37, 1202-19.
7. Heid HW, Moll R, Schwetlick I, Rackwitz HR, Keenan TW. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases. Cell Tissue Res, 1998, 294, 309-21.
8. Chao FF, Stiers DL, Ontko JA. Hepatocellular triglyceride synthesis and transfer to lipid droplets and nascent very low density lipoproteins. J Lipid Res, 1986, 27, 1174-81.
9. Tran K, Thorne-Tjomsland G, DeLong CJ, et al. Intracellular assembly of very low density lipoproteins containing apolipoprotein B100 in rat hepatoma McA-RH777 cells. J Biol Chem, 2002, 277, 31187-200.
10. Liao W, Yeung SCJ, Chan L. Proteasome-mediated degradation of apolipoprotein B targets both nascent peptides cotranslationally before translocation and full-length apolipoprotein B after translocation into the endoplamic reticulum. J Biol Chem, 1998, 273, 27225-30.
11. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Ann Rev Biochem, 1980, 49, 395-420.
12. Fromenty B, Pessayre D. Inhibition of mitochondrial β-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther, 1995, 67, 101-54.
13. Salway JG, ed. Metabolism at a glance. Blackwell Scientific Publications, Oxford, 1994, 28-78.
14. Nemoto S, Takeda K, Yu ZX, Ferrans VJ, Finkel T. Role of mitochondrial oxidants as regulators of cellular metabolism. Mol Cell Biol, 2000, 20, 7311-8.
15. Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. J Bioenerg Biomembr, 1997, 29, 131-49.
16. Bogenhagen DF. Repair of mtDNA in vertebrates. Am J Hum Genet, 1999, 64, 1276-81.
17. Croteau DL, Stierum RH, Bohr VA. Mitochondrial DNA repair pathways. Mutat Res, 1999, 434, 137-48.
18. Demeilliers C, Maisonneuve C, Grodet A, et al. Impaired adaptive resynthesis and prolonged depletion of hepatic mitochondrial DNA after repeated alcohol binges in mice. Gastroenterology, 2002, 123, 1278-90.
19. Berson A, De Beco V, Lettéron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 1998, 114, 764-74.
20. Farrell GC. Drugs and steatohepatitis. Sem Liver Dis, 2002, 22, 185-94.
21. Cortez-Pinto H, Baptista A, Camilo ME, de Costa EB, Valente A, de Moura MC. Tamoxifen-associated steatohepatitis-report of three cases. J Hepatol, 1995, 23, 95-7.
22. Hu B, French SW. 2',3'-Dideoxyinosine-induced Mallory bodies in patients with HIV. Am J Clin Pathol, 1997, 108, 280-3.
23. Coglan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis, 2001, 33, 1914-21.
24. Van Huyen JP, Landau A, Piketty C, et al. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver. Value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. Am J Clin Pathol, 2003, 119, 546-55.
25. Lettéron P, Sutton A, Mansouri A, Fromenty B, Pessayre D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology, 2003, 38, 133-40.
26. Cahill A, Cunningham CC, Ishii H, Bailey SM, Fromenty B, Davies A. Effects of alcohol and oxidative stress on liver pathology: the role of the mitochondrion. Alcohol Clin Exp Res, 2002, 26, 907-15.
27. Chariot P, Drogou I, de Lacroix-Szmania I, et al. Zidovudine-induced mitochondrial disorder with massive liver steatosis, myopathy, lactic acidosis, and mitochondrial DNA depletion. J Hepatol, 1999, 30, 156-60.
28. Gaou I, Malliti M, Guimont MC, et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther, 2001, 297, 516-23.
29. Note R, Maisonneuve C, Lettéron P, et al. Mitochondrial and metabolic effects of nucleoside reverse-transcriptase inhibitors (NRTIs) in mice receiving one of five single- and three dual-NRTI treatments. Antimicrob Agents Chemother, 2003, 47, 3384-92.
30. Hayakawa M, Ogawa T, Sugiyama S, Tanaka M, Ozawa T. Massive conversion of guanosine to 8-hydroxy-guanosine in mouse liver mitochondrial DNA by administration of azidothymidine. Biochem Biophys Res Commun, 1991, 176, 87-93.
31. Garcia de la Asuncion J, del Olmo ML, Sastre J, et al. AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest, 1998, 102, 4-9.
32. Richter C, Park JW, Ames BN. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA, 1988, 85, 6465-7.
33. Pinz KG, Shibutani S, Bogenhagen DF. Action of mitochondrial DNA polymerase γ at sites of base loss or oxidative damage. J Biol Chem, 1995, 270, 9202-6.
34. Martin AM, Hammond E, Nolan D, et al. Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors. Am J Hum Genet, 2003, 72, 549-60.
35. Bartley PB, Westacott L, Boots RJ, et al. Large hepatic mitochondrial DNA deletions associated with L-lactic acidosis and highly active anti-retroviral therapy. AIDS, 2001, 15, 419-20.
36. Berneburg M, Grether-Beck S, Kürten V, et al. Singlet oxygen mediates the UVA-induced generation of photoaging-associated mitochondrial common deletion. J Biol Chem, 1999, 274, 15345-49.
37. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues. Is mitochondrial toxicity the only mechanism? Drug Safety, 2000, 23, 467-81.
38. Elimadi A, Morin D, Albengres E, et al. Differential effects of zidovudine and zidovudine triphosphate on mitochondrial permeability transition and oxidative phosphorylation. Br J Pharmacol, 1997, 121, 1295-300.
39. Barile M, Valenti D, Passarella S, Quagliariello E. 3'-Azido-3'deoxythymidine uptake into isolated rat liver mitochondria and impairment of ADP/ATP translocator. Biochemical Pharmacol, 1997, 53, 913-20.
40. Fromenty B, Fisch C, Labbe G, et al. Amiodarone inhibits the mitochondrial β-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther, 1990, 255, 1371-6.
41. Fromenty B, Fisch C, Berson A, Lettéron P, Larrey D, Pessayre D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and II. J Pharmacol Exp Ther, 1990, 255, 1377-84.
42. Deschamps D, De Beco V, Fisch C, Fromenty B, Guillouzo A, Pessayre D. Inhibition by perhexiline of oxidative phosphorylation and the β-oxidation of fatty acids: possible role in pseudoalcoholic liver lesions. Hepatology, 1994, 19, 948-61.
43. Berson A, de Beco V, Lettéron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology, 1998, 114, 764-74.
44. Fromenty B, Lettéron P, Fish C, Berson A, Deschamps D, Pessayre D. Evaluation of human blood lymphocytes as a model to study, the effects of drugs on human mitochondria. Effects of low concentrations of amiodarone on fatty acid oxidation, ATP levels and cell survival. Biochem Pharmacol, 1993, 45, 421-32.
45. Tuquet C, Dupont J, Mesneau A, Roussaux J. Effects of tamoxifen on the electron transport chain of isolated rat liver mitochondria. Cell Biol Toxicol, 2000, 16, 207-19.
46. Cardoso CMP, Custodio JBA, Almeida LM, Moreno AJM. Mechanisms of the deleterious effects of tamoxifen on mitochondrial respiration rate and phosphorylation efficiency. Toxicol Appl Pharmacol, 2001, 176, 145-52.
47. Igoudjil A, Maisonneuve C, Note R, Lettéron P, Djouadi F, Pessayre D, Fromenty B. L-carnitine prevents mitochondrial and metabolic disturbances induced by very high dose of stavudine in mice [Abstract]. Tenth Conference on Retroviruses and Opportunistic Infections (CROI). 10-14 February 2003, Boston.
48. Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor α mediates the adaptive response to fasting. J Clin Invest, 1999, 103, 1489-98.
49. Georges B, Galland S, Rigault C, Le Borgne F, Demarquoy J. Beneficial effects of L-carnitine in myoblastic C2C12 cells. Interaction with zidovudine. Biochem Pharmacol, 2003, 65, 1483-8.
50. Semino-Mora MC, Leon-Monzon ME, Dalakas MC. The effect of L-carnitine on the AZT-induced destruction of human myotubes. Part II: treatment with L-carnitine improves the AZT-induced changes and prevents further destruction. Lab Invest, 1994, 71, 773-81.
51. Shepherd PR, Kahn BB. Glucose transporters and insulin action. Implications for insulin resistance and diabetes mellitus. N Engl J Med, 1999, 341, 248-57.
52. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature, 2002, 420, 353-6.
53. Chitturi S, Abeygunasekera S, Farrell GC, et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance. Hepatology, 2002, 35, 373-9.
54. Attie AD, Krauss RM, Gray-Keller MP, et al. Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res, 2002, 43, 1899-907.
55. Gorden ES. Non-esterified fatty acids in blood of obese and lean subjects. Am J Clin Nutr, 1960, 8, 740-7.
56. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers of two mouse models of diabetes mellitus. J Biol Chem, 1999, 274, 30028-32.
57. Matsusue K, Haluzik M, Lambert G, et al. Liver specific disruption of PPAR-γ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J Clin Invest, 2003, 111, 737-47.
58. Charlton M, Sreekumar R, Rasmussen D, Lindor K, Nair S. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology, 2002, 35, 898-904.
59. Musso G, Gambino R, De Michieli F, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology, 2003, 37, 909-16.
60. Sreekumar R, Rosado B, Rasmussen D, Charlton M. Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology, 2003, 38, 244-51.
61. Taghibiglou C, Carpentier A, Van Iderstine SC, et al. Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular apoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem, 2000, 275, 8416-25.
62. Perlemuter G, Sabile A, Lettéron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J, 2002, 16, 185-94.
63. Lin MC, Li JJ, Wang EJ, Princler GL, Kauffman FC, Kung HF. Ethanol down-regulates the transcription of microsomal triglyceride transfer protein gene. FASEB, J 1997, 11, 1145-52.
64. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology, 2001, 120, 1183-92.
65. Chalasani N, Gorki JC, Asghar MS, et al. Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis. Hepatology, 2003, 37, 544-50.
66. Brady LJ, Brady PS, Romsos DR, Hoppel CL. Elevated hepatic mitochondrial and peroxisomal oxidative capacities in fed and starved adult obese (ob/ob) mice. Biochem J, 1985, 231, 439-44.
67. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology, 2003, 37, 343-50.
68. Cook GA, Gamble MS. Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. J Biol Chem, 1987, 262, 2050-55.
69. Memon RA, Tecott LH, Nonogaki K, et al. Up-regulation of peroxisome proliferator-activated receptors (PPAR-α) and PPAR-γ messenger ribonucleic acid expression in the liver in murine obesity: troglitazone induces expression of PPAR-γ-responsive adipose tissue-specific genes in the liver of obese diabetic mice. Endocrinology, 2000, 41, 4021-31.
70. Nakatani T, Tsuboyama-Kasaoka N, Takahashi M, Miura S, Ezaki O. Mechanism for peroxisome proliferator-activated receptor-α activator-induced up-regulation of UCP-2 mRNA in rodent hepatocytes. J Biol Chem, 2002, 277, 9562-9.
71. Serra D, Casals N, Asins G, Royo T, Ciudad CJ, Hegardt FG. Regulation of mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A synthase protein by starvation, fat feeding, and diabetes. Arch Biochem Biophys, 1993, 307, 40-5.
72. Collins JC, Scheinberg IH, Giblin DR, Sternlieb I. Hepatic peroxisomal abnormalities in abetalipoproteinemia. Gastroenterology, 1989, 97, 766-70.
73. De Craemer D, Pauwels M, Van den Branden C. Alterations of peroxisomes in steatosis of the human liver: a quantitative study. Hepatology, 1995, 22, 744-52.
74. Kante A, Malki MC, Coquard C, Latruffe N. Metabolic control of the expression of mitochondrial hydroxybutyrate dehydrogenase, a ketone body converting enzyme. Biochim Biophys Acta, 1990, 1033, 291-7.
75. Chavin KD, Yang S, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem, 1999, 274, 5692-700.
76. Cortez-Pinto H, Chatham J, Chacko VP, Arnold C, Rashid A, Diehl AM. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis. A pilot study. JAMA, 1999, 282, 1659-64.
77. Fleury C, Sanchis D. The mitochondrial uncoupling protein-2: current status. Int J Biochem Cell Biol, 1999, 31, 1261-78.
78. Himms-Hagen J, Harper ME. Physiological role of UCP-3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. Exp Biol Med, 2001, 226, 78-84.
79. Ježek P. Possible physiological roles of mitochondrial uncoupling proteins-UCPn. Int J Biochem Cell Biol, 2002, 34, 1190-206.
80. Baffy G, Zhang CY, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology, 2002, 35, 753-61.
81. Spahr L, Negro F, Leandro G, et al. Impaired hepatic mitochondrial oxidation using the 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis. Med Sci Monit, 2003, 9, CR6-11.
82. Quash G, Fournet G, Reichert U. Anaplerotic reactions in tumor proliferation and apoptosis. Biochem Pharmacol, 2003, 66, 365-70.
83. Caldwell SH, Swerdlow RH, Khan EM, et al. Mitochondrial abnormalities in nonalcoholic steatohepatitis. J Hepatol, 1999, 31, 430-4.
84. Haque M, Mirshahi F, Campbell-Sargent C, et al. Nonalcoholic steatohepatitis (NASH) is associated with hepatocyte mitochondrial DNA depletion [Abstract]. Hepatology, 2002, 36, 403.
85. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink JA, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS, 1998, 12, 1735-44.
86. Ducluzeau PH, Lachaux A, Bouvier R, Streichenberger N, Stepien G, Mousson B. Depletion of mitochondrial DNA associated with infantile cholestasis and progressive liver fibrosis. J Hepatol, 1999, 30, 149-55.
87. Ducluzeau PH, Lachaux A, Bouvier R, et al. Progressive reversion of clinical and molecular phenotype in a child with liver mitochondrial DNA depletion. J Hepatol, 2002, 36, 698-703.
88. Santamaria E, Avila MA, Latasa MU, et al. Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of S-adenosylmethionine. Proc Natl Acad Sci USA, 2003, 100, 3065-70.
89. Pérez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology, 2003, 38, 999-1007.
90. Schulze-Osthoff K, Bakker AC, Vanhaesebroeck B, Beyaert R, Jacob WA, Fiers W. Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem, 1992, 267, 5317-23.
91. West IV. Radicals and oxidative stress in diabetes. Diabet Med, 2000, 17, 171-80.
92. Turko IV, Li L, Aulak KS, Stuehr DJ, Chang JY, Murad F. Protein tyrosine nitration in the mitochondria from diabetic mouse heart. Implications to dysfunctional mitochondria in diabetes. J Biol Chem, 2003, 278, 33972-7.
93. Young T, Cunningham CC, Bailey SM. Reactive oxygen species production by the mitochondrial respiratory, chain in isolated rat hepatocytes and liver mitochondria: studies using myxothiazol. Arch Biochem Biophys, 2002, 405, 65-72.
94. + oxidation-reduction state. Biochem J, 2002, 368, 545-53.
95. Yamagishi S, Edelstein D, Du X, Kaneda Y, Guzman M, Brownlee M. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem, 2001, 276, 25096-100.
96. St-Pierre J, Buckingham JA, Roebuck SJ, Brand MD. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J Biol Chem, 2002, 277, 44784-90.
97. Du XL, Edelstein D, Rossetti L, et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA, 2000, 97, 12222-6.
98. Yang SQ, Zhu H, Li Y, et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys, 2000, 378, 259-68.
99. 2 generation in liver mitochondria. Carcinogenesis, 2000, 21, 983-9.
100. Koteish A, Diehl AM. Animal models of steatosis. Sem Liver Dis, 2001, 21, 89-104.
101. Rao MS, Papreddy K, Musunuri S, Okonkwo A. Prevention/reversal of choline deficiency-induced steatohepatitis by a peroxisome proliferator-activated receptor alpha ligand in rats. In Vivo, 2002, 16, 145-52.
102. Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with non-alcoholic steatohepatitis. Hepatology, 1998, 27, 128-33.
103. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Sem Liver Dis, 2001, 21, 27-41.
104. Robin MA, Anandatheerthavarada HK, Fang JK, Cudic M, Otros Otvos L, Avadhani NG. Mitochondrial targeted cytochrome P450 2E (P450 MT5) contains an intact N terminus and requires mitochondrial specific transfer proteins for activity. J Biol Chem, 2001, 276, 24680-9.
105. Robin MA, Anandatheerthavarada HK, Biswas G, et al. Bimodal targeting of microsomal CYP2E1 to mitochondrial through activation of an N-terminal chimeric signal by cAMP-mediated phosphorylation. J Biol Chem, 2002, 277, 40583-93.
106. Raza H, Prabu SK, Robin MA, Avadhani NG. Elevated mitochondrial cytochrome P450 2E1 and glutathione S-transferase A4-4 in streptozotocin-induced diabetic rats: tissue specific variations and roles in oxidative stress. Diabetes, 2004, 53, 185-94.
107. Leclercq IA, Field J, Enriquez A, Farrell GC, Robertson GR. Constitutive and inducible expression of hepatic CYP2E1 in leptin-deficient ob/ob mice. Biochem Biophys Res Commun, 2000, 268, 337-44.
108. Kono H, Rusyn I, Yin M, et al. NADPH oxidase-derived free radicals are key oxidants in alcohol-induced liver disease. J Clin Invest, 2000, 106, 867-72.
109. Fiorini RN, Shafizadeh SF, Chavin KD. Primary non-function in steatotic livers is due to differential Toll-like expression and endotoxin sensitivity [Abstract]. Hepatology, 2002, 36, 198.
110. Enomoto N, Takei Y, Hirose M, et al. Thalidomide prevents alcoholic liver injury in rats through suppression of Kupffer cell sensitization and TNF-α production. Gastroenterology, 2002, 123, 291-300.
111. Lettéron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol, 1996, 24, 200-8.
112. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, Robertson GR. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine non-alcoholic steatohepatitis. J Clin Invest, 2001, 105, 1067-75.
113. Hruszkewycz AM. Evidence for mitochondrial DNA damage by lipid peroxidation. Biochem Biophys Res Commun, 1988, 153, 191-7.
114. Hruszkewycz AM, Bergtold DS. The 8-hydroxyguanine content of isolated mitochondria increases with lipid peroxidation. Mutat Res, 1990, 244, 123-8.
115. Chen J, Schenker S, Frosto TA, Hensderson GI. Inhibition of cytochrome c oxidase activity by 4-hydroxynonenal (HNE). Role of HNE adduct formation with the enzyme catalytic site. Biochem Biophys Acta, 1998, 1380, 336-44.
116. Chen J, Petersen DR, Schenker S, Hensderson GI. Formation of malondialdehyde adducts in livers of rats exposed to ethanol: role of ethanol-mediated inhibition of cytochrome c oxidase. Alcohol Clin Exp Res 2000, 24, 544-52.
117. Matsuhashi T, Liu X, Nishizawa Y, Usukura J, Wozniak M, Wakabayashi T. Mechanism of the formation of megamitochondria in the mouse liver induced by chloramphenicol. Toxicol Lett, 1996, 86, 47-54.
118. Wakabayashi T. Megamitochondria formation. Physiology and pathology. J Cell Mol Med, 2002, 6, 497-538.
119. Kristal BS, Park BK, Yu BP. 4-Hydroxyhexenal is a potent inducer of the mitochondrial permeability transition. J Biol Chem, 1996, 271, 6033-8.
120. Antonetti DA, Reynet C, Kahn CR. Increased expression of mitochondrial-encoded genes in skeletal muscle of humans with diabetes mellitus. J Clin Invest, 1995, 95, 1383-8.
121. Liang P, Hughes V, Fukagawa NK. Increased prevalence of mitochondrial DNA deletions in skeletal muscle of older individuals with impaired glucose tolerance. Possible marker of glycemic stress. Diabetes, 1997, 46, 920-3.
122. Lee HK, Song JH, Shin CS, et al. Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract, 1998, 42, 161-7.
123. Kakimoto M, Inoguchi T, Sonta T, et al. Accumulation of 8-hydroxy-2'-deoxyguanosine and mitochondrial DNA deletion in kidney of diabetic rats. Diabetes, 2002, 51, 1588-95.
124. Yin M, Gäbele E, Wheeler MD, et al. Alcohol-induced free radicals in mice: direct toxicants or signaling molecules? Hepatology, 2001, 34, 935-42.
125. Barnett CR, Abbott RA, Bailey CJ, Flatt PR, Ionnides C. Cytochrome P450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes. Biochem Pharmacol, 1992, 43, 1868-71.
126. Strauss RS. Comparison of serum concentrations of α-tocopherol and β-carotene in a cross-sectional sample of obese and nonobese children (NHANES III). J Pediatr, 1999, 134, 160-5.
127. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr, 2000, 136, 734-8.
128. Roberts EA. Steatohepatitis in children. Best Prac Res Clin Gastroenterol, 2002, 16, 749-65.
129. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Sem Liver Dis, 2001, 21, 17-26.
130. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci USA, 1994, 91, 10771-8.
131. Hagen TM, Yowe DL, Bartholomew JC, et al. Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase. Proc Natl Acad Sci USA, 1997, 94, 3064-9.
132. Müller-Höcker J, Aust D, Rohrbach H, et al. Defects of the respiratory chain in the normal human liver and in cirrhosis during aging. Hepatology, 1997, 26, 709-19.
133. De la Asuncion JG, Millan A, Pla R, et al. Mitochondrial glutathione oxidation correlates with age-associated oxidative damage to mitochondrial DNA. FASEB J, 1996, 10, 333-8.
134. Bellentani S, Saccoccio G, Masutti F, et al. Prevalence and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med, 2000, 132, 112-7.
135. Fromenty B, Grimbert S, Mansouri A, et al. Hepatic mitochondrial DNA deletion in alcoholics: Association with microvesicular steatosis. Gastroenterology, 1995, 108, 193-200.
136. Mansouri A, Gaou I, de Kerguence C, et al. An alcoholic binge causes massive degradation of hepatic mitochondrial DNA in mice. Gastroenterology, 1999, 117, 181-90.
137. Mansouri A, Fromenty B, Berson A, et al. Multiple hepatic mitochondrial DNA deletions suggest premature oxidative aging in alcoholic patient. J Hepatol, 1997, 27, 96-102.
138. Hoek JB, Cahill A, Pastorino JG. Alcohol and mitochondria: a dysfunctional relationship. Gastroenterology, 2002, 122, 2049-63.
139. Pessayre D, Mansouri A, Haouzi D, Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol, 1999, 15, 367-73.
140. Pessayre D, Feldmann G, Haouzi D, Fau D, Moreau A, Neuman M. Hepatocyte apoptosis triggered by natural substances (cytokines, other endogenous substances and foreign toxins). In: RG Cameron, G. Feuer, eds. Apoptosis and its Modulation by Drugs, Springer Verlag: Heidelberg. Handbook of Experimental Pharmacology, 2000, 142, 59-108.
141. Crespo J, Cayon A, Fernadez-Gil P, et al. Gene expression of tumor necrosis factor αand TNF-receptors p55 and p75 in nonalcoholic steatohepatitis patients. Hepatology, 2001, 34, 1158-63.
142. Feldmann G, Haouzi D, Moreau A, et al. Opening of the mitochondrial permeability transition pore causes matrix expansion and outer membrane rupture in Fas-mediated hepatic apoptosis in mice. Hepatology, 2000, 31, 674-83.
143. Natori S, Rust C, Stadheim LM, Srinivasan A, Burgart LJ, Gores GJ. Hepatocyte apoptosis is a pathologic feature of human alcoholic hepatitis. J Hepatol, 2001, 34, 248-53.
144. Rodriguez CM, Cortez-Pinto H, Sola S, et al. Apoptosis is a prominent feature of human alcoholic and non-alcoholic steatohepatitis [Abstract]. Hepatology, 2001, 34, 672.
145. Kim JS, Qian T, Lemasters JJ. Mitochondrial permeability transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes. Gastroenterology, 2003, 124, 494-503.
146. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology, 2002, 35, 62-73.
147. Leonarduzzi G, Scavazza A, Biasi F, et al. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth factor β1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J, 1997, 11, 851-7.
148. Parola M, Pinzani M, Casini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α1 (I) gene expression in human liver, fat-storing cells. Biochem Biophys Res Commun, 1993, 194, 1044-50.
149. Phung N, Farrell G, Robertson G, George J. Vitamin E but not glutathione precursors inhibits hepatic fibrosis in experimental NASH exhibiting oxidative stress and mitochondrial abnormalities [Abstract]. Hepatology, 2001, 34, 361.
150. Hasegawa T, Yoneda M, Nakamura K, Makino I, Terano A. Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2001, 15, 1667-72.
151. Leclercq IA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol, 2002, 37, 206-13.
152. Tang M, Potter JJ, Mezey E. Leptin enhances the effect of transforming growth factor beta in increasing type I collagen formation. Biochem Biophys Res Commun, 2002, 297, 906-11.
153. Ikejima K, Takei Y, Honda H, et al. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology, 2002, 122, 1399-400.
154. Saxena NK, Ikeda K, Rockey DC, Friedman SL, Anania FA. Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells in lean littermates of ob/ob mice. Hepatology, 2002, 35, 762-71.
155. Friedman JM and Halaas JL. Leptin and the regulation of body weight in mammals. Nature, 1998, 395, 763-70.
156. Chitturi S, Farrell G, Frost L, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity. Hepatology, 2002, 36, 403-9.
157. Valenti L, Fracanzani AL, Dongiovanni P, et al. Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology, 2002, 122, 274-80.
158. Bernard S, Touzet S, Personne I, et al. Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes. Diabetologia, 2000, 43, 995-9.
159. Day CP, Saksena S, Leathart J, Burt A, James O, Daly A. Genetic evidence supporting the two-hit model of NASH pathogenesis [Abstract]. Hepatology, 2002, 36, 382.
160. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature, 1997, 389, 610-4.
161. Feingold KR, Grunfeld C. Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J Clin Invest, 1987, 80, 184-90.
162. Suematsu N, Tsutsui H, Wen J, et al. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation, 2003, 107, 1418-23.
163. Tarugi P, Lonardo A, Ballarini G, et al. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol, 2000, 33, 361-70.
164. George DK, Goldwurm S, MacDonald GA, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology, 1998, 114, 311-8.
165. Bonkovsky HL, Jawaid Q, Tortorelli K, et al. Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol, 1999, 31, 421-9.
166. Hellerbrand C, Mühlbauer M, Meiler C, et al. Influence of a functional polymorphism of the LPS receptor CD14 on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection [Abstract]. Hepatology, 2002, 36, 400.
167. Degoul F, Sutton A, Mansouri A, et al. Homozygosity for alanine in the mitochondrial targeting sequence of manganese superoxide dismutase and alcohol liver disease. Gastroenterology, 2001, 120, 1468-74.
168. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F. The Ala-9Val dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogentics, 2003, 13, 145-57.
169. Capron JP, Delamarre J, Dupas JL, Braillon A, Degott C, Quenum C. Fasting in obesity. Another cause of liver injury with alcoholic hyaline? Dig Dis Sci, 1982, 27, 265-8.
170. Pessayre D, Dolder A, Artigou JY, et al. Effect of fasting on metabolite-mediated hepatotoxicity in the rat, Gastroenterology, 1979, 77, 264-71.
171. Haouzi D, Lekehal M, Tinel M, et al. Prolonged, but not acute, glutathione depletion promotes Fas-mediated mitochondrial permeability transition and apoptosis in mice. Hepatology, 2001, 33, 1181-8.
172. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese leptin-deficient mice. J Clin Invest, 2000, 6, 998-1003.
173. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet, 2001, 358, 893-4.
174. Neuschwander-Tetri BA, Brunt E, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology, 2003, 38, 1008-17.
175. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol, 1999, 31, 384.
176. Ip E, Farrell GC, Robertson G, Hall P, Kirsch R, Leclercq I. Central role of PPAR-α dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology, 2003, 38, 123-32.
177. Merat S, Malekzadeh R, Sohrabi MR, et al. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol, 2003, 38, 414-8.
178. Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterology, 2001, 96, 2711-7.
179. Liang LJ, Yin XY, Luo SM, Zheng JF, Lu MD, Huang JF. A study of the ameliorating effects of carnitine on hepatic steatosis induced by total parental nutritional in rats. World J Gastroenterol, 1999, 5, 312-5.
180. Walter JH. L-carnitine. Arch Dis Child, 1996, 74, 475-8.